Bent Ejlertsen
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Papers in
- Cancer Research 107
- Breast Cancer Treatment Studies 90
- Cancer Genomics and Diagnostics 16
- Oncology 93
- HER2/EGFR in Cancer Research 42
- Cancer Treatment and Pharmacology 28
- Co-authors
- Maj‐Britt Jensen (89 shared papers)Henning T. Mouridsen (41 shared papers)Peer Christiansen (31 shared papers)Ann Søegaard Knoop (32 shared papers)Niels T. Kroman (25 shared papers)Birgitte Rasmussen (18 shared papers)Eva Balslev (30 shared papers)Kirsten Vang Nielsen (13 shared papers)
- Journals
- Acta Oncologica (49 papers)Breast Cancer Research and Treatment (25 papers)European Journal of Cancer (17 papers)Journal of Clinical Oncology (17 papers)Breast Cancer Research (11 papers)
- Partner nations
- DenmarkUnited StatesUnited Kingdom
In The Last Decade
Bent Ejlertsen
252 papers receiving 15.3k citations
Bent Ejlertsen's Hit Papers
Peers
Comparison fields: 5 of 155
- Cancer Research 5.5k
- Oncology 5.8k
- Genetics 2.9k
- Pathology and Forensic Medicine 1.2k
- Pulmonary and Respiratory Medicine 1.9k
Countries citing papers authored by Bent Ejlertsen
This map shows the geographic impact of Bent Ejlertsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bent Ejlertsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bent Ejlertsen more than expected).
Fields of papers citing papers by Bent Ejlertsen
This network shows the impact of papers produced by Bent Ejlertsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bent Ejlertsen. The network helps show where Bent Ejlertsen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bent Ejlertsen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 259 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2950 |
| 2 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 915 |
| 3 | 2013 | 463 | |
| 4 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 5 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2016 | 455 |
| 6 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer Hit paper breakdown → | 2015 | 397 |
| 7 | 2013 | 328 | |
| 8 | 2011 | 310 | |
| 9 | 2017 | 298 | |
| 10 | 2005 | 269 | |
| 11 | 2008 | 244 | |
| 12 | 2018 | 242 | |
| 13 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Hit paper breakdown → | 2021 | 241 |
| 14 | 2021 | 236 | |
| 15 | 2016 | 194 | |
| 16 | 1994 | 171 | |
| 17 | 2020 | 170 | |
| 18 | 2015 | 164 | |
| 19 | 2011 | 158 | |
| 20 | 2015 | 144 |
About Bent Ejlertsen
Bent Ejlertsen is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 259 papers that have together received 15.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (42 papers), BRCA gene mutations in cancer (36 papers), Cancer Treatment and Pharmacology (28 papers), Estrogen and related hormone effects (24 papers), Cancer Genomics and Diagnostics (16 papers), Advanced Breast Cancer Therapies (15 papers) and Breast Lesions and Carcinomas (11 papers). The work is most often cited by research in Cancer Research (5.5k citations), Oncology (5.8k citations), Genetics (2.9k citations), Pathology and Forensic Medicine (1.2k citations) and Pulmonary and Respiratory Medicine (1.9k citations). Bent Ejlertsen has collaborated with scholars based in Denmark, United States and United Kingdom. Frequent co-authors include Maj‐Britt Jensen, Henning T. Mouridsen, Peer Christiansen, Ann Søegaard Knoop, Niels T. Kroman, Birgitte Rasmussen, Eva Balslev, Kirsten Vang Nielsen, Deirdre Cronin-Fenton and Anne‐Vibeke Lænkholm. Their work appears in journals such as Acta Oncologica, Breast Cancer Research and Treatment, European Journal of Cancer, Journal of Clinical Oncology and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.